Biopharmaceutical companies Kamada and Kedrion Biopharma have partnered to develop, manufacture and distribute a human plasma-derived polyclonal immunoglobulin (IgG) product for potential Covid-19 treatment.
The partners will leverage Kamada’s IgG platform technology to develop and manufacture the anti-SARS-CoV-2 IgG product. Under the collaboration, Kedrion will collect and provide plasma at its KEDPLASMA centres from recovered Covid-19 patients.
Kamada will carry out product development, manufacturing, clinical development, in collaboration with Kedrion and regulatory filings.
Kedrion Biopharma CEO Paolo Marcucci said: “In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on